Cost Effectiveness of Herpes Zoster Vaccine in Canada

被引：0
作者：
Mehdi Najafzadeh
Carlo A. Marra
Eleni Galanis
David M. Patrick
机构：
[1] University of British Columbia,Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences
[2] BC Centre for Disease Control,Epidemiology Services
[3] University of British Columbia,Department of Healthcare and Epidemiology
[4] Centre for Health Evaluation and Outcome Sciences (CHEOS),undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Herpes Zoster; Varicella Zoster Virus; Human Papilloma Virus Vaccine; Varicella Zoster Virus Infection; Vaccine Cost;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Herpes zoster (HZ), or shingles, results from reactivation of latent varicella zoster virus in the sensory ganglia of adults, and results in significant morbidity in the elderly, including the development of postherpetic neuralgia (PHN). The lifetime risk of HZ is about 20–30% and the incidence increases with age. The protective effect of the HZ vaccine has been shown in a large clinical trial; however, the effectiveness of the vaccine decreased with age of vaccination.
引用
收藏
页码：991 / 1004
页数：13
相关论文
共 62 条
[1]  
Brisson M(2001)Epidemiology of varicella zoster virus infection in Canada and the United Kingdom Epidemiol Infect 127 305-14
[2]  
Edmunds WJ(2007)The burden of varicella and zoster in British Columbia 1994-2003: baseline assessment prior to universal vaccination Can Commun Dis Rep 33 1-15
[3]  
Law B(1996)Pain and its persistence in herpes zoster Pain 67 241-51
[4]  
Edgar BL(2007)Evaluation of the costeffectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults Vaccine 25 8326-37
[5]  
Galanis E(2005)Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey J Pain 6 356-63
[6]  
Kay C(2005)A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2271-84
[7]  
Dworkin RH(2007)The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada Vaccine 25 5399-408
[8]  
Portenoy RK(2007)Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis Vaccine 25 5433-40
[9]  
Pellissier JM(1998)Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect J Infect Dis 178 109-12
[10]  
Brisson M(2001)The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales Vaccine 19 3076-90
1234567